erlotinib

Erlotinib (NSC-718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC50 of 2 nM for human EGFR. Erlotinib D6 is a deuterium labeled Erlotinib .

Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM. Erlotinib D6 hydrochloride a deuterium labeled Erlotinib Hydrochloride.

Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1]. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1].Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process[2]. [1]. Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57(21), 4838-4848.[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

Desmethyl Erlotinib (CP-473420) is the active metabolite of Erlotinib (EGFR inhibitor with IC50 of 2 nM).

Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

Erlotinib is an epidermal growth factor receptor inhibitor. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor.

Desmethyl Erlotinib hydrochloride (OSI 420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for human EGFR and EGFR autophosphorylation in tumor cells.

TD52 is an orally active inhibitor of cancerous inhibitor of PP2A (CIP2A). TD52 is an Erlotinib derivative and indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter.

Erlotinib-13C6 HCl is the 13C labeled compound of Erlotinib HCl. Erlotinib HCl has a CAS number of 183321-74-6. Erlotinib is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

Erlotinib hydrochloride (Standard) is a reference standard for research and analysis in studies involving Erlotinib hydrochloride. Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

CP-457493 is a bio-active chemical.

TM608 is a potent selective c-Met inhibitor that targets mitochondria and kills erlotinib-resistant lung cancer cells, rapidly accumulates in mitochondria, and inhibits MET activation in high MET expression, erlotinib-resistant HCC827B cells (total cell l

WZ4002-hydroxyl is a WZ4002 derivative or WZ4002 analogue in which methoxy is replaced by hydroxyl and can be detected in 50% of patients with clinical resistance to gefitinib or erlotinib. WZ4002 has a basic chemical skeleton (covalent pyrimidine) that d

TD52 dihydrochloride (TD52 2HCl), a derivative of Erlotinib, is a potent and orally active inhibitor of protein phosphatase 2A (CIP2A). It exhibits strong anti-cancer properties by regulating the CIP2A/PP2A/p-Akt signaling pathway, resulting in the induction of apoptosis in triple-negative breast cancer (TNBC) cells. Mechanistically, TD52 dihydrochloride disrupts the binding of Elk1 to the CIP2A promoter, effectively reducing CIP2A levels. Notably, TD52 dihydrochloride demonstrates powerful anti-cancer activity while displaying less inhibition of p-EGFR.

4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a building block and synthetic intermediate.1,2,3,4,5It has been used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer compounds.1,2,3It is also a synthetic intermediate in the synthesis of EGFR inhibitors, including erlotinib , with antiproliferative activity.4,5

SB02024 is a VPS34 inhibitor. SB02024 activates cGAS-STING signaling and sensitizes tumors to STING agonist. SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo. Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer.

CH5164840 is a potent, oral allosteric HSP90 inhibitor (IC50 = 4.1 nM). It suppresses tumor growth by degrading client proteins like HER2 and Akt in cancer research.

Erasin is a STAT3 inhibitor (IC50 = 9.7 μM) with higher selectivity for inhibiting STAT3 tyrosine phosphorylation than STAT5 and STAT1. It induces apoptosis in various cancer cell lines (e.g., MDA-MB-231, HCC-827) and is effective against Erlotinib-resistant cancer cells.

SIQ17, an EGFR inhibitor, blocks the ATP-binding site with an IC50 of 0.62 nM, demonstrating more effective EGFR-TK inhibitory activity than the known inhibitor Erlotinib (IC50 of ∼20 nM). SIQ17 is applicable in cancer research [1].

EGFR-TK-IN-3 (3) acts as an inhibitor of EGFR, exhibiting an IC50 value of 2.33 μM in Erlotinib-resistant A549 cells.

OSI-413 (free base) (CP 373413) is the primary metabolite of Erlotinib. Erlotinib (CP-358774) acts as a direct EGFR tyrosine kinase inhibitor with an IC50 of 2 nM against human EGFR.